Nano-Pharmacokinetics and Theranostics

Advancing Cancer Therapy

1st Edition - July 28, 2021
Imprint: Academic Press
Editors: Nanasaheb D. Thorat, Nitesh Kumar
Language: English
Paperback ISBN:
9 7 8 - 0 - 3 2 3 - 8 5 0 5 0 - 6
eBook ISBN:
9 7 8 - 0 - 3 2 3 - 8 5 9 8 2 - 0

Nano-Pharmacokinetics and Theranostics: Advancing Cancer Therapy addresses from a comprehensive and multidisciplinary approach the translational aspects and clinical perspecti… Read more

Purchase options

BLOOM INTO SPRING SAVINGS

Save up to 25% on books and eBooks!

Shop now

Institutional subscription on ScienceDirect

Request a sales quote

Nano-Pharmacokinetics and Theranostics: Advancing Cancer Therapy addresses from a comprehensive and multidisciplinary approach the translational aspects and clinical perspectives of nano-pharmacokinetics using cancer as a model disease. Nano-pharmacokinetics is emerging as an important sub discipline of nanoscience and medical sciences because of the increasing safety issues of nanosystems on living organisms. This book reports the dynamics of nanosystems in living organisms for better understanding of nanotoxicity, pharmacology, biochemistry, physiology and medicine perspectives. It further examines current progress of state-of-the art pharmacokinetics mechanisms, which will be of great help to develop more clinical-oriented nanosystems with a wide safety margin. The book is divided into three sections: the first section focuses on the concept of pharmacokinetics with state-of-the-art Nano-Pharmacokinetics (NPK). The second section looks at the engineering of nanoparticles and pharmacokinetics clinical development. The final section focuses on Nano-Pharmacokinetics and Theranostics, elaborating the basic question of how pharmacokinetics of nanomaterials relate to their end applications such as cancer therapy. Nano-Pharmacokinetics and Theranostics: Advancing Cancer Therapy will be useful to researchers in the field of nanoparticle based targeted drug delivery including pharmaceutical scientists, material scientists, chemists, nanotechnologists, biomedical scientists, and clinicians.

Cover image
Title page
Table of Contents
Copyright
List of contributors
About the editors
Preface
Acknowledgment
Chapter 1. Nanomaterials and pharmacokinetics
Abstract
1.1 Introduction
1.2 Pharmacokinetics of nanomaterials
1.3 Governing parameters for pharmacokinetics of nanomaterials
1.4 Prime issues in the pharmacokinetics of nanomaterials
1.5 Challenges and future perspectives
1.6 Conclusions
Acknowledgment
Conflict of interest
References
Chapter 2. Nanopharmacokinetics: routes of administration and predictive models for nanopharmacokinetics
Abstract
2.1 Introduction
2.2 Modes of administration routes of nanocarriers
2.3 Types of targeted drug delivery methods
2.4 Physiologically based pharmacokinetic modeling
2.5 Conclusion and future perspective
Acknowledgement
References
Chapter 3. Nano-pharmacokinetics: interface of physics, chemistry and biology
Abstract
3.1 Introduction
3.2 Physical parameters
3.3 Chemical parameters
3.4 Biological parameters
3.5 Conclusion
References
Chapter 4. Nanomaterials exposure to human
Abstract
4.1 Introduction
4.2 Mechanism of release of engineered/manufactured nanomaterials
4.3 Routes of exposure of nanomaterials
4.4 Health effects associated with the exposure of nanomaterials
4.5 Discussion and future perspectives
Acknowledgement
References
Chapter 5. Engineered nanomaterials and pharmacokinetics
Abstract
5.1 Introduction
5.2 Cancer and engineered nanoparticles
5.3 Engineered gold nanoparticles and its pharmacokinetics studies
5.4 Engineered silver nanoparticles and its pharmacokinetics studies
5.5 Engineered quantum dots and its pharmacokinetics studies
5.6 Engineered carbon nanotubes and its pharmacokinetics studies
5.7 Engineered polymeric nanoparticle and its pharmacokinetics studies
5.8 Engineered titanium dioxide nanoparticles and its pharmacokinetics studies
5.9 Engineered graphene and its pharmacokinetics studies
5.10 Engineered fullerenes and its pharmacokinetics studies
5.11 Engineered mesoporous nanoparticles and its pharmacokinetic Studies
5.12 Engineered dendrimers and its pharmacokinetics studies
5.13 Engineered iron oxide nanoparticles and its pharmacokinetics studies
5.14 Conclusion
References
Chapter 6. Regulatory, safety, and toxicological concerns of nanomaterials with their manufacturing issues
Abstract
6.1 Introduction
6.2 Safety concerns
6.3 Ethical implications of nanotechnology
6.4 Manufacturing
6.5 Regulation
6.6 Conclusions
References
Chapter 7. Nano-pharmacokinetics: biodistribution and toxicology
Abstract
7.1 Introduction
7.2 Pharmacokinetic aspects of nanomedicines
7.3 Role of nanomaterials in pharmacokinetics of nanomedicines
7.4 Biodistribution and clearance aspects of nanotheranostics
7.5 Toxicological aspects of nanomedicines
References
Chapter 8. Biological systems and nanopharmacokinetics
Abstract
8.1 Uptake of nanoparticles into biological system
8.2 Nanoparticles and extracellular matrix
8.3 Interaction of nanoparticles with tumor microenvironment
8.4 Intracellular degradation and excretion of nanoparticles
8.5 Conclusions
References
Chapter 9. Nanopharmacokinetics assessment
Abstract
9.1 Introduction
9.2 Kinetic homogeneity
9.3 Concentration–response relationship
9.4 Drug absorption
9.5 Simple math equations to describe drug disposition
9.6 Common PK parameters assessment during absorption phase
9.7 Bioavailability
9.8 Alterations in absorption kinetics in nanodrugs
9.9 Biodistribution of nanoparticles
9.10 Metabolism of nanoparticles
9.11 Elimination
9.12 Assessment of in vitro drug release
9.13 Spectroscopic analytical methods for nanomedicines
References
Chapter 10. Clinical protocols for nanopharmacokinetics assessment
Abstract
10.1 Introduction
10.2 Theranostics in clinical trials
10.3 General consideration of regulations for nanomaterials
10.4 Regulatory pathway for theranostics
10.5 Regulatory prospective on nanotheranostics
10.6 Guidance provided by different regulatory bodies
10.7 Conclusion
Acknowledgments
References
Chapter 11. Nano-pharmacokinetics and cancer theranostics
Abstract
11.1 Introduction
11.2 Pharmacokinetics of nanoformulation
11.3 Physiological properties of nanoformulation
11.4 Pharmacokinetics of nanoformulation
11.5 Pharmacodynamics and clinical significance
11.6 Conclusion
11.7 Future direction
References
Chapter 12. Nanopharmacokinetics: key role in in vivo imaging
Abstract
12.1 Introduction
12.2 Conjugated gold nanoparticles
12.3 Ruthenium selenium nanohybrid
12.4 Conjugated silica nanoparticles
12.5 Metal oxide liquid crystalline nanostructures
12.6 Calcium phosphate nanoparticles
12.7 Graphene-based nanoconjugates
12.8 Conclusion and future scope
Acknowledgements
References
Chapter 13. Pharmacokinetics/pharmacodynamics and clinical relationship
Abstract
13.1 Introduction
13.2 Nanoscale delivery systems
13.3 Pharmacokinetics and pharmacodynamics
13.4 Impacting factors of pharmacokinetics/pharmacodynamics of nanoscale delivery systems
13.5 Clinical relationships
13.6 Conclusion
References
Further reading
Chapter 14. Nano-pharmacokinetics preclinical to clinical translation
Abstract
14.1 Commercial and practical feasibility
14.2 Current trends in the clinical translation of nanomedicines
14.3 Other Challenges in the clinical translation of nanomedicines
References
Chapter 15. Nano-pharmacokinetics: industrial transformation future outlook and conclusion
Abstract
15.1 Introduction
15.2 Characterization of nanomedicine
15.3 Conclusions and future outlook
Acknowledgment
Conflict of Interest
References
Index

Nanasaheb D. Thorat

Dr. Nanasaheb Thorat is Principal Investigator funded by the Science Foundation Ireland (SFI) and Irish Research Council (IRC) Pathway Program at the University of Limerick, Ireland. He is also a Marie Curie Visiting Research Scientist at the University of Oxford, UK.

He has been deeply engaged in collaborative work with the many eminent scientists from Japan, USA, Germany, Korea, Ireland, India, Poland, Saudi Arabia and Australia. Dr. Thorat has received the European Commission’s innovation Radar “Grand Prix of the Innovation Radar Prize 2020” for developing ground-breaking technology for breast cancer theranostics.

Affiliations and expertise

Principal Investigator, University of Limerick,, Ireland

Nitesh Kumar

Dr. Nitesh Kumar, M Pharm, PhD is an Assistant Professor from the Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Hajipur. Dr. Kumar has published 90 peer reviewed journal articles (total citations – 995 and H-index – 19) and 2 book chapters. He delivered talks and oral presentations at several scientific conferences and received awards for his research contributions. Dr. Kumar has more than 10 years of teaching and research experience and currently guiding and co-guiding 12 PhD students on their thesis work. His research work includes biocompatibility and toxicological evaluation of various drug molecules and biomedical devices namely dialysis catridges, tooth implant and electrical stimulator for glioma treatment. His other research areas are neuroprotection, hepatoprotection and neuropharmacological studies of synthesized and herbal compounds. In addition to his scientific contributions, Dr. Kumar collaborated with several government agencies and industries in India and successfully implemented projects of high impact value with successful research outcomes as principal investigator, lead investigator and co-investigator.

Affiliations and expertise

Assistant Professor, Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Hajipur (NIPER-H), Export Promotions Industrial Park (EPIP), Industrial Area Hajipur, Bihar, India

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health